Center-Authored Papers

Filters: Author is Lin, Daniel W  [Clear All Filters]
A
Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter BH, Klotz L et al..  2014.  The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Soci. Archives of pathology & laboratory medicine. Abstract
Ankerst DP, Xia J, Thompson IM, Hoefler J, Newcomb LF, Brooks JD, Carroll PR, Ellis WJ, Gleave ME, Lance RS et al..  2015.  Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator.. European urology. Abstract
B
Bhindi B, Karnes JR, Rangel LJ, Mason RJ, Gettman MT, Frank I, Tollefson MK, Lin DW, Thompson HR, Boorjian SA.  2017.  Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.. The Journal of urology. Abstract
Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, Rubin MA, van der Kwast T, Amin M, Epstein JI.  2012.  Contemporary Grading for Prostate Cancer: Implications for Patient Care.. European urology. Abstract
Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA et al..  2015.  Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.. PloS one. 10(7):e0132343. Abstract
Brooks JD, Wei W, Pollack JR, West RB, Shin JH, Sunwoo JB, Hawley SJ, Auman H, Newcomb LF, Simko J et al..  2016.  Loss of expression of AZGP1 is associated with worse clinical outcomes in a multi-institutional radical prostatectomy cohort.. The Prostate. 76(15):1409-1419. Abstract
Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, Kattan MW, Lin DW.  2017.  Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.. CA: a cancer journal for clinicians. Abstract
C
Cheng HH, Lin DW, Yu EY.  2012.  Advanced clinical States in prostate cancer.. The Urologic clinics of North America. 39(4):561-71. Abstract
Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS.  2017.  Prostate Cancer Screening in a New Era of Genetics.. Clinical genitourinary cancer. Abstract
D
Dean JP, Sprenger CC, Wan J, Haugk K, Ellis WJ, Lin DW, Corman JM, Dalkin BL, Mostaghel E, Nelson PS et al..  2013.  Response of the Insulin-Like Growth Factor (IGF) System to IGF-IR Inhibition and Androgen Deprivation in a Neoadjuvant Prostate Cancer Trial: Effects of Obesity and Androgen Deprivation.. The Journal of clinical endocrinology and metabolism. 98(5):E820-8. Abstract
Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL et al..  2015.  Active surveillance for prostate cancer: the role of the pathologist.. Pathology. 47(1):1-3.
E
Eminaga O, Wei W, Hawley SJ, Auman H, Newcomb LF, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave ME et al..  2016.  MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.. PloS one. 11(11):e0165236. Abstract
Etzioni R, Gulati R, Lin DW.  2015.  Measures of survival benefit in cancer drug development and their limitations.. Urologic oncology. 33(3):122-7. Abstract
G
Geybels MS, Wright JL, Bibikova M, Klotzle B, Fan J-B, Zhao S, Feng Z, Ostrander EA, Lin DW, Nelson PS et al..  2016.  Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.. Clinical epigenetics. 8:97. Abstract
Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR.  2008.  Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.. Cancer causes & control : CCC. 19(1):25-31. Abstract
Gore JL, du Plessis M, Santiago-Jiménez M, Yousefi K, Thompson DJS, Karsh L, Lane BR, Franks M, Chen DYT, Bandyk M et al..  2017.  Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.. Cancer. Abstract
H
Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M et al..  2013.  A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray.. Advances in anatomic pathology. 20(1):39-44. Abstract
Holt SK, Kwon EM, Lin DW, Ostrander EA, Stanford JL.  2010.  Association of hepsin gene variants with prostate cancer risk and prognosis.. The Prostate. 70(9):1012-9. Abstract
Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z, Ostrander EA, Peters U, Stanford JL.  2010.  Vitamin D pathway gene variants and prostate cancer prognosis.. The Prostate. 70(13):1448-60. Abstract
Hu JC, Lin DW.  2012.  Current status of focal primary therapy for prostate cancer.. Urologic oncology. 30(6):942-3.
I
Izard JP, True LD, May P, Ellis WJ, Lange PH, Dalkin B, Lin DW, Schmidt RA, Wright JL.  2014.  Prostate Cancer That Is Within 0.1 mm of the Surgical Margin of a Radical Prostatectomy Predicts Greater Likelihood of Recurrence.. The American journal of surgical pathology. 38(3):333-8. Abstract
J
James AC, Lee FC, Izard JP, Harris WP, Cheng HH, Zhao S, Gore JL, Lin DW, Porter MP, Yu EY et al..  2014.  Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer.. Clinical genitourinary cancer. Abstract
James AC, Lin DW, Wright JL.  2014.  Neobladders and continent catheterizable stomas for the bladder cancer survivor.. Current opinion in urology. Abstract
K
Kearns JT, Lin DW.  2017.  Prediction models for prostate cancer outcomes: what is the state of the art in 2017? Current opinion in urology. Abstract
Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD.  2010.  Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.. The Prostate. 70(6):584-90. Abstract